Goldenwell Biotech (GWLL) Non-Current Debt (2023 - 2025)

Goldenwell Biotech has reported Non-Current Debt for 3 years, with the latest figure at $95588.0 in Q1 2025.

• For the quarter ending Q1 2025, Non-Current Debt changed N/A year-over-year to $95588.0; the trailing twelve-month figure through Mar 2025 stood at $95588.0 (changed N/A YoY), and the FY2024 full-year result was $95588.0, up 26.46% from the prior year.
• Non-Current Debt for Q1 2025 stood at $95588.0, roughly flat from $95588.0 in the prior quarter.
• The five-year high for Non-Current Debt was $95588.0 in Q4 2024, with the low at $75588.0 in Q4 2023.
• Historically, Non-Current Debt has averaged $88921.3 across 3 years, with a median of $95588.0 in 2024.
• The largest YoY upside for Non-Current Debt was 26.46% in 2024 against a maximum downside of 26.46% in 2024.
• Goldenwell Biotech's Non-Current Debt stood at $75588.0 in 2023, then climbed by 26.46% to $95588.0 in 2024, then changed by 0.0% to $95588.0 in 2025.
• The last three Non-Current Debt figures came in at $95588.0 (Q1 2025), $95588.0 (Q4 2024), and $75588.0 (Q4 2023), per Business Quant data.